The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario.

Trial Profile

The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Zotarolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms TWENTE
  • Most Recent Events

    • 04 Sep 2013 Two-year results according to gender presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
    • 09 Feb 2012 Results published in the Journal of the American College of Cardiology.
    • 28 Aug 2010 During the first 16 months of study 1005 out of 1104 (91%) eligible patients were included - this represents 73% of the inclusion target, as reported in an abstract at ESC Congress 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top